935 related articles for article (PubMed ID: 28341383)
1. Utilization of gynecologic services in women with breast cancer receiving hormonal therapy.
Wright JD; Desai VB; Chen L; Burke WM; Tergas AI; Hou JY; Accordino M; Ananth CV; Neugut AI; Hershman DL
Am J Obstet Gynecol; 2017 Jul; 217(1):59.e1-59.e12. PubMed ID: 28341383
[TBL] [Abstract][Full Text] [Related]
2. Indication of hysteroscopy in tamoxifen treated breast cancer patients.
Taponeco F; Curcio C; Fasciani A; Giuntini A; Artini PG; Fornaciari G; Petraglia F; Genazzani AR
J Exp Clin Cancer Res; 2002 Mar; 21(1):37-43. PubMed ID: 12071527
[TBL] [Abstract][Full Text] [Related]
3. Risk Factors Associated with Endometrial Pathology in Premenopausal Breast Cancer Patients Treated with Tamoxifen.
Lee M; Piao J; Jeon MJ
Yonsei Med J; 2020 Apr; 61(4):317-322. PubMed ID: 32233174
[TBL] [Abstract][Full Text] [Related]
4. Comparison of endometrial changes among symptomatic tamoxifen-treated and nontreated premenopausal and postmenopausal breast cancer patients.
Cheng WF; Lin HH; Torng PL; Huang SC
Gynecol Oncol; 1997 Aug; 66(2):233-7. PubMed ID: 9264568
[TBL] [Abstract][Full Text] [Related]
5. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
Chalas E; Costantino JP; Wickerham DL; Wolmark N; Lewis GC; Bergman C; Runowicz CD
Am J Obstet Gynecol; 2005 Apr; 192(4):1230-7; discussion 1237-9. PubMed ID: 15846210
[TBL] [Abstract][Full Text] [Related]
6. Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients.
Morales L; Timmerman D; Neven P; Konstantinovic ML; Carbonez A; Van Huffel S; Ameye L; Weltens C; Christiaens MR; Vergote I; Paridaens R
Ann Oncol; 2005 Jan; 16(1):70-4. PubMed ID: 15598941
[TBL] [Abstract][Full Text] [Related]
7. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
8. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Amir E; Seruga B; Niraula S; Carlsson L; Ocaña A
J Natl Cancer Inst; 2011 Sep; 103(17):1299-309. PubMed ID: 21743022
[TBL] [Abstract][Full Text] [Related]
9. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
11. [Uterine abnormalities in non menopausal women who received tamoxifen for breast cancer adjuvant therapy].
d'Arailh AS; Michy T; Pioud R; Dravet F; Classe JM
Gynecol Obstet Fertil; 2007 Dec; 35(12):1215-9. PubMed ID: 18035581
[TBL] [Abstract][Full Text] [Related]
12. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients.
Markovitch O; Tepper R; Fishman A; Aviram R; Cohen I
Breast Cancer Res Treat; 2009 Jan; 113(2):321-6. PubMed ID: 18297393
[TBL] [Abstract][Full Text] [Related]
13. Hysteroscopic Evaluation of Endometrial Changes in Breast Cancer Women with or without Hormone Therapies: Results from a Large Multicenter Cohort Study.
Chiofalo B; Mazzon I; Di Angelo Antonio S; Amadore D; Vizza E; Laganà AS; Vocaturo G; Calagna G; Favilli A; Palmara V; Maranto M; Vitale SG; Cucinella G; Granese R; Ghezzi F; Sperduti I; Triolo O
J Minim Invasive Gynecol; 2020; 27(4):832-839. PubMed ID: 31425735
[TBL] [Abstract][Full Text] [Related]
14. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
15. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen.
Fung MF; Reid A; Faught W; Le T; Chenier C; Verma S; Brydon E; Fung KF
Gynecol Oncol; 2003 Oct; 91(1):154-9. PubMed ID: 14529676
[TBL] [Abstract][Full Text] [Related]
16. The ATAC adjuvant breast cancer trial in postmenopausal women: baseline endometrial subprotocol data.
Duffy S; Jackson TL; Lansdown M; Philips K; Wells M; Pollard S; Clack G; Cuzick J; Coibion M; Bianco AR
BJOG; 2003 Dec; 110(12):1099-106. PubMed ID: 14664881
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole versus tamoxifen treatment in postmenopausal women with endocrine-responsive breast cancer and tamoxifen-induced endometrial pathology.
Gerber B; Krause A; Reimer T; Mylonas I; Makovitzky J; Kundt G; Janni W
Clin Cancer Res; 2006 Feb; 12(4):1245-50. PubMed ID: 16489080
[TBL] [Abstract][Full Text] [Related]
19. Transvaginal sonographic and hysteroscopic findings in postmenopausal women receiving tamoxifen.
Marconi D; Exacoustos C; Cangi B; Perroni A; Zupi E; Valli E; Romanini C
J Am Assoc Gynecol Laparosc; 1997 May; 4(3):331-9. PubMed ID: 9154782
[TBL] [Abstract][Full Text] [Related]
20. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
Runowicz CD; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Ford LG; Vogel VG; Wolmark N
Am J Obstet Gynecol; 2011 Dec; 205(6):535.e1-5. PubMed ID: 21872200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
